Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $10.29 Average Price Target from Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULCGet Free Report) has received a consensus rating of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.29.

Separately, The Goldman Sachs Group lifted their price objective on shares of Fulcrum Therapeutics from $5.00 to $6.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th.

Get Our Latest Report on Fulcrum Therapeutics

Fulcrum Therapeutics Stock Down 0.3 %

Shares of FULC opened at $7.22 on Thursday. The company has a market cap of $446.34 million, a price-to-earnings ratio of -4.30 and a beta of 2.25. Fulcrum Therapeutics has a twelve month low of $2.25 and a twelve month high of $14.10. The company has a 50 day moving average of $6.20 and a two-hundred day moving average of $4.93.

Fulcrum Therapeutics (NASDAQ:FULCGet Free Report) last announced its earnings results on Tuesday, November 7th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05. Fulcrum Therapeutics had a negative net margin of 3,769.15% and a negative return on equity of 38.48%. The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $1.81 million. On average, sell-side analysts expect that Fulcrum Therapeutics will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FULC. MetLife Investment Management LLC increased its holdings in Fulcrum Therapeutics by 57.0% in the first quarter. MetLife Investment Management LLC now owns 15,001 shares of the company’s stock valued at $355,000 after buying an additional 5,446 shares in the last quarter. Rhumbline Advisers increased its holdings in Fulcrum Therapeutics by 7.6% in the first quarter. Rhumbline Advisers now owns 34,115 shares of the company’s stock valued at $807,000 after buying an additional 2,408 shares in the last quarter. BlackRock Inc. increased its holdings in Fulcrum Therapeutics by 0.9% in the first quarter. BlackRock Inc. now owns 2,228,610 shares of the company’s stock valued at $52,707,000 after buying an additional 20,532 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Fulcrum Therapeutics by 50.8% in the first quarter. Dimensional Fund Advisors LP now owns 282,793 shares of the company’s stock valued at $6,688,000 after buying an additional 95,272 shares in the last quarter. Finally, Lord Abbett & CO. LLC increased its stake in shares of Fulcrum Therapeutics by 1.8% during the first quarter. Lord Abbett & CO. LLC now owns 188,651 shares of the company’s stock worth $4,462,000 after purchasing an additional 3,417 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

(Get Free Report

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial.

Featured Articles

Analyst Recommendations for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.